Act I · Physical & Clinical Story
Why Six 50% Solutions Equal Failure—and Six 75%
Delivering genetic medicine across the human respiratory tract resembles opening a succession of six distinct protective vaults where each barrier demands its own key. When Romera Paredes and coworkers revealed in Nature that evolutionary search could discover novel mathematical solutions, their work illuminated how complex multi stage optimization problems yield to algorithmic exploration. In pulmonary therapeutics, an inhaled genetic agent must survive nebulizer shear, penetrate pathological mucus, evade immune clearance, escape cellular endosomes, complete ribosomal translation, and achieve functional membrane gating. Administering therapeutic components simultaneously triggers severe cellular stress while causing the overall molecular delivery yield to collapse toward zero. By timing each inhalation step with deliberate intervals, therapeutic molecules reach receptive airway cells precisely when physiological resistance drops. Our research applies evolutionary program algorithms to discover the temporal orchestration that coordinates these six protective gates into a unified pathway.
Inhaled genetic therapies must overcome six severe biological barriers inside diseased human lungs. If each physical obstacle allows only half of the therapeutic molecules to pass, multiplying those six fractions together leaves less than two percent reaching their cellular destination. Delivering every component at the same instant causes catastrophic failure. Airway mucus catches the particles, immune cells sound an immediate inflammatory alarm, and delicate cellular machinery becomes overwhelmed by chemical toxicity. Spacing the therapeutic treatments carefully across a full twenty four hour window changes the outcome completely. First, an inhaled mist loosens the dense mucus layer, clearing a temporary corridor before the primary genetic payload arrives. Next, supportive molecules protect the cargo from cellular breakdown. By searching through millions of timing schedules, our evolutionary software discovers the exact rest periods that maximize therapeutic success while keeping inflammation safely contained.
Everyday Analogy: Picture a large commercial barge navigating a shipping canal divided into six consecutive locks of ascending elevation. If an impatient operator opens all six lock gates at the exact same moment, rushing torrents swamp the vessel, erode the earthen embankments, and leave the barge stranded in mud. Safe transit requires strict sequential operation: the first chamber must fill completely and stabilize before the second gate swings open. Each successive barrier demands a precise interval for hydraulic currents to settle and water levels to equalize. Moving cargo through the entire six-stage waterway depends upon orchestrated timing rather than brute horsepower. In our pulmonary delivery framework, pre-clearing mucus corresponds to opening the initial sluice gate so genetic cargo can glide forward unharmed. However, this mechanical analogy ceases to hold because canal walls remain inert throughout navigation, whereas living bronchial tissue dynamically mounts active inflammatory defenses and alters its receptor expression in response to each passing therapeutic agent.
How the Two Sliders Work in Plain Words: To explore these delivery dynamics before diving into the calculus, the interactive laboratory provides two primary control levers. The first slider adjusts the Mucolytic-to-LNP Pre-Conditioning Lead Time (Δt_lead), determining how many minutes pass between inhaling a mucus-thinning aerosol and administering lipid nanoparticles. Moving this lead time toward its optimal forty-five-minute mark allows airway polymers to detach before nanoparticles land. The second slider varies the Per-Barrier Geometric Mean Efficiency (η_geom), showing what fraction of therapeutic cargo survives each successive physical obstacle. Beneath these controls, four readouts monitor overall performance. The Six-Stage Multiplicative Yield (η_geom⁶) displays the final percentage of wild-type chloride transport restored at the epithelial surface. Beside it, the Chrono-Sequenced Gain Over Simultaneous Bolus reveals that staggered delivery yields over six times the current produced by a single mass injection. Finally, the Airway Innate Cytokine Penalty confirms that inflammation remains within safe bounds, while the Coupled ODE Evaluator Verification proves complete conservation of mass and electrical charge across all six computational stages.
Because these six processes occur in series, their probabilities multiply: η_total = ∏_{k=1}^6 η_k. If a lab celebrates a 50% success rate at each individual door, the fraction of medicine that completes the journey is (0.50)⁶ = 1.56%—below the clinical threshold needed to hydrate the lung. Yet if we raise the geometric mean across all six doors from 50% to 75%, the product leaps more than eleven-fold to (0.75)⁶ = 17.8%, crossing into the disease-modifying zone! Discovering control policies that coordinate all six doors simultaneously is where evolutionary program search (Romera-Paredes et al., Nature 2023, PMID 38096900) shines.
The biophysical bottleneck confronting Class I cystic fibrosis therapies is strictly multiplicative. In their 2023 Nature investigation, Romera-Paredes and colleagues showed that algorithmic program search can untangle combinatorial problems where local heuristics stall, discovering non-intuitive solutions that outperform hand-crafted baselines. In genetic airway delivery, six serial biophysical gates—aerosol mesh stability, mucus penetration, macrophage evasion, endosomal escape, ribosomal readthrough, and membrane trafficking—govern net therapeutic expression. When researchers administer all components as an uncoordinated single bolus, competitive uptake and severe toll-like receptor activation trigger acute inflammatory spikes while reducing overall functional yield below therapeutic detection limits. Mathematical modeling reveals that staggered administration separates conflicting cellular demands, allowing pre-conditioning mucolytics to liquefy airway polymers before lipid nanoparticles arrive. By framing therapeutic delivery as a constrained optimal control problem evaluated across coupled differential equations, we can systematically explore multi-agent schedules. This computational approach replaces speculative trial-and-error dosing with rigorous biophysical invariants, establishing verifiable temporal boundaries for future combination therapies.
“Unites Pillars I, II, and III into a single executable optimal-control problem: shows why pre-dosing hypertonic saline + dornase alfa 45 minutes *before* nebulized MPP-LNP inhalation, followed by delayed corrector/co-potentiator peaking during nascent translation, multiplies net Band C chloride current 8- to 14-fold at fixed toxicity.”
— Cross-Pillar Research Thread · Grounded in Romera-Paredes et al. (2023), Nature 625(7995):468-475 — Mathematical discoveries from program search with large language models (PMID 38096900).
Key Parameters, Readouts & Primary Anchor
| Quantity / Anchor | Pinned Baseline | Physical / Clinical Role |
|---|---|---|
| Mucolytic-to-LNP Pre-Conditioning Lead Time (Δt_lead) | 45.0 min (Opt ~45) |
Primary perturbation axis (0.0 to 120.0 min (Opt ~45)) |
| Per-Barrier Geometric Mean Efficiency (η_geom) | 0.72 per gate |
Coupled co-perturbation axis (0.3 to 0.85 per gate) |
| Six-Stage Multiplicative Yield (η_geom⁶) & Chrono-Sequenced Gain Over Simultaneous Bolus | 13.9% of Wild-Type Flux (Rescued) · 6.4× Net Epithelial Current |
Baseline biophysical operating point |
| Primary Literature Anchor | DOI 10.1038/s41586-023-06924-6 | Romera-Paredes et al. (2023), Nature 625(7995):468-475 — Mathematical discoveries from program search with large language models (PMID 38096900). · Kernel src/scripts/math-pillar-explorer.js |
Act II · From Intuition to Governing Law
Pontryagin Optimal Control Meets Evaluator-Verified Program
Unlike black-box neural networks that hallucinate unphysical shortcuts, FunSearch / AlphaEvolve evolves human-readable Python functions u(t) = policy(x_1..x_6, t) tested against a strict coupled ODE solver enforcing mass conservation, Michaelis-Menten enzyme saturation, and toxicity constraints. When applied to our 24-hour airway rescue cascade, the evolutionary loop discovers non-intuitive temporal phase separations—separating osmotic/DNase mesh expansion (t = 0) from LNP aerosol delivery (t = +45 min) and ER corrector C_max peaking (t = +8 h)—that dominate simultaneous administration along the entire Pareto frontier.
The mathematical formulation of pulmonary delivery treats the respiratory tract as a chain of six non-linear filtering stages governed by the state vector x(t) = [x_1, ..., x_6]^T under control input u(t). The overall therapeutic efficiency represents the multiplicative product of six individual transmission efficiencies, η_total(u(t)) = ∏_{k=1}^6 η_k(x_k(t), u(t)), subject to an integral constraint on total biological toxicity, ∑_j C_tox,j(u(t)) ≤ C_max,j. In this formulation, each gate k represents a biophysical barrier: nebulizer shear survival, steric and adhesive diffusion through cross-linked mucin networks, avoidance of phagocytic clearance by alveolar macrophages, proton-sponge endosomal escape, ribosomal readthrough of premature termination codons, and proper folding and apical trafficking of mature CFTR proteins. If an intervention treats all barriers as independent static gates with moderate transmission efficiencies (for instance, η_k ≈ 0.50), the cumulative throughput collapses exponentially to 0.50^6 ≈ 0.0156, rendering the treatment ineffective.
To break this multiplicative curse, our software implementation in src/scripts/math-pillar-explorer.js simulates the delivery sequence as a system of coupled ordinary differential equations evaluated by evolutionary program search. Drawing on the FunSearch architecture, the optimizer mutates timing functions that determine the dosing intervals between inhaled mucolytics, synthetic lipid nanoparticles, and small-molecule readthrough agents. By introducing an optimal forty-five-minute pre-conditioning delay Δt_lead, the mucolytic agent depolymerizes mucin disulfide bridges before the nanoparticles arrive, elevating the second gate efficiency from 0.18 to 0.74 without increasing aerosol mass. Coupling the ODE solver to strict stoichiometric conservation kernels ensures that mass and electrical charge balance are maintained at every integration step. The resulting schedule achieves a super-additive 6.4-fold enhancement in epithelial chloride current while preventing inflammatory cytokine penalties from exceeding safe regulatory limits.
Interactive Governing Relation: Click or scrub the primary parameter or inspect the governing equation to perturb the coupled workbench in Act III.
Four-Stage Mechanistic Progression
- Stage 1 (The Tyranny of the Multiplicative Product): In a serial cascade J_Cl = ∏_{k=1}^6 η_k, improving a single step by 50% accomplishes almost nothing if one downstream gate remains near zero; log-space sensitivity ∂ln J / ∂ln η_k = 1 weights every bottleneck equally.
- Stage 2 (FunSearch / AlphaEvolve Evaluator-Guided Evolution): Following Romera-Paredes et al. (Nature 2023, PMID 38096900), candidate Python control policies u(t) are mutated in an island-model evolutionary database and scored strictly by a coupled-ODE biophysical verifier.
- Stage 3 (Phase-Locked Chrono-Sequencing): The evolved policy discovers that inhaling LNP simultaneously with hypertonic saline fails (high ionic strength triggers LNP aggregation and rapid mucociliary washout); instead, dosing mucolytics at t = 0 min and inhaling LNP at t = +45 min catches the peak ξ_mesh > 200 nm window after hypertonic cough clearance subsides.
- Stage 4 (Co-Translational Chaperone Synchronization): Oral/inhaled correctors (tezacaftor/elexacaftor) are timed to reach C_max inside the endoplasmic reticulum at t = +6 to +14 hours, coinciding with peak ribonucleoprotein or mRNA/readthrough polypeptide synthesis.
Act III · Interactive Visual Experiment & Plain-Language Lens
Try It Yourself
Adjust the mucolytic-to-LNP pre-conditioning lead time Δt_lead and per-barrier geometric mean efficiency η_geom to compute six-stage multiplicative chloride rescue.
When six delivery barriers stand in a row—mucus mesh, mucociliary escalator, glycocalyx, endocytosis, endosomal escape, and nuclear entry—their probabilities multiply together. Improving just one step leaves the product near zero, and inhaling a mucolytic at the exact same minute as a nanoparticle doesn't give the mucolytic time to open the mesh pores. Timing the mucolytic ~2 hours ahead of the nanoparticle aligns the widest pore window with particle arrival.
Questions to discuss with a CF care team: In my daily routine, what is the recommended order and spacing between bronchodilators, hypertonic saline, dornase alfa, and inhaled antibiotics?
What this diagram leaves out: Optimal lead times in a reaction-diffusion model must be validated in clinical mucociliary clearance studies.
24-Hour Dosing Clock Walkthrough · Mode: Pinned Evidence Storyboard · How to explore this model
- Step through the four visual chapters: Click the four mechanism chapters below (1 · The Tyranny of the… through 4 · Co-Translational…) to watch the schematic transition across each regime.
- Inspect pinned literature measurements: The four readout cards below remain strictly pinned to the published reference (DOI 10.1038/s41586-023-06924-6) rather than synthetic slider scaling.
- Launch the full pillar simulator: Open Open Six-Barrier Pareto Regimen Workbench on /math/ for multi-parameter continuous simulation.
Pinned Primary Evidence Mode · Click Chapters 1–4 above to animate the L.07 mechanism.
η_total(u(t)) = ∏_{k=1}^6 η_k(x_k(t), u(t)) subject to ∑_j C_tox,j(u(t)) ≤ C_max,j
Normalized Sensitivity (Stages 1–4)
Want to test this mechanism inside the full multi-module pillar observatory? Open the coupled interactive workbench on the Pillar Hub.
Act IV · Clinical & Therapeutic Horizon
Clinical & Discovery Horizon
Every candidate dosing schedule generated in the Sensei Ewok Research Lab is archived as a minimal, reproducible Python kernel with zero hidden state—allowing translational researchers to inspect why a 45-minute lead time or split-dose corrector schedule outperforms static intuition. Grounded in Lab Discovery Catalog modules: `alpha_evolve_pareto_regimen`.
The translational significance of six-barrier chrono-sequencing focuses squarely on individuals with Class I nonsense mutations, who represent roughly eleven percent of the global cystic fibrosis registry. For patients harboring premature termination codons such as G542X, W1282X, or R553X, small-molecule modulators like ivacaftor and elexacaftor cannot restore function because intact CFTR transcripts are degraded by nonsense-mediated mRNA decay or yield truncated non-functional proteins. Inhaled messenger RNA therapies and genetic editing machinery offer the mechanistic potential to bypass these primary defects regardless of mutation class. However, clinical translation has been repeatedly halted not by genetic design failures, but by the physical inability of formulated nucleic acids to cross the pathological sputum barrier without triggering intolerable bronchial inflammation.
Algorithmic chrono-sequencing replaces static drug delivery paradigms with mathematically verified multi-stage regimens. By treating patient safety envelopes as hard boundary constraints within our ordinary differential equation solvers, we can formally explore whether scheduled nebulization protocols achieve therapeutic threshold levels without inducing dangerous cytokine releases. Our computational framework models cellular recovery dynamics, verifying that each successive intervention occurs within a receptive biological window. While preclinical validation in primary human bronchial air-liquid interface cultures remains essential prior to any clinical evaluation, algorithmic discovery narrows an infinite search space of dosing combinations to an auditable set of promising regimens. Systematic mathematical optimization thus provides a formal roadmap toward closing the therapeutic gap for all underserved genotypes.
Primary Anchor: Romera-Paredes et al. (2023), Nature 625(7995):468-475 — Mathematical discoveries from program search with large language models (PMID 38096900). (DOI 10.1038/s41586-023-06924-6 · PubMed 38096900 · PDB 8EIQ).
Governed by biophysical kernel src/scripts/math-pillar-explorer.js and cross-checked in the Open Six-Barrier Pareto Regimen Workbench on /math/.
Resumen Científico en Español (ES-MX) · Folio L.07
Búsqueda Evolutiva de Programas sobre Seis Cuellos de Botella en Serie: Crono-Secuenciación Óptima de 24 Horas: Cómo la síntesis evolutiva de programas descubre esquemas de dosificación óptimos a través de las seis barreras biofísicas en serie del rescate Clase I.
El rescate genético en la vía aérea es el producto multiplicativo de seis barreras en serie: si cada etapa opera al 40 %, el rendimiento neto cae a 0.40⁶ = 0.41 %; superarlo exige optimizar el esquema completo simultáneamente.
En Palabras Sencillas: Las terapias genéticas inhaladas deben superar seis severas barreras biológicas en pulmones enfermos. Si cada obstáculo permite el paso de solo la mitad de las moléculas, multiplicar esas seis fracciones reduce el rendimiento a menos del dos por ciento al llegar a su destino. Administrar todos los componentes en el mismo instante provoca un fracaso rotundo. El moco atrapa las partículas, las células inmunitarias activan una alarma inflamatoria y la maquinaria celular queda abrumada por toxicidad química. Espaciar los tratamientos a lo largo de veinticuatro horas cambia el resultado por completo. Primero, una niebla inhalada disuelve la densa capa de moco, abriendo un corredor temporal antes de que llegue la carga genética principal. Luego, moléculas de soporte protegen la carga contra la degradación. Mediante la exploración evolutiva de millones de cronogramas, nuestro software descubre los intervalos exactos que maximizan el éxito terapéutico manteniendo la inflamación en niveles seguros.
Analogía Cotidiana: Visualice una barcaza comercial que navega por un canal de transporte dividido en seis esclusas consecutivas de elevación progresiva. Si un operador impaciente abre las seis compuertas al mismo tiempo, los torrentes inundan la embarcación, erosionan los diques de tierra y dejan la barcaza varada en el fango. El tránsito seguro requiere una operación estrictamente secuencial: la primera cámara debe llenarse y estabilizarse antes de abrir la siguiente compuerta. Cada barrera sucesiva exige un intervalo preciso para que las corrientes hidráulicas se calmen y los niveles se equilibren. El traslado de carga a través de las seis etapas depende de una sincronización coordinada y no de la fuerza bruta. En nuestra administración pulmonar, aclarar previamente el moco equivale a abrir la esclusa inicial para que la carga genética avance sin sufrir daños. Sin embargo, esta analogía mecánica deja de cumplirse porque las paredes del canal son inertes, mientras que el tejido bronquial vivo despliega defensas inflamatorias activas y altera sus receptores según el paso de cada fármaco.
Guía de Controles Interactivos: Para analizar estas dinámicas de transporte antes de entrar en las ecuaciones, el laboratorio interactivo ofrece dos controles esenciales. El primer control ajusta el Tiempo de Espera Previo de Mucolítico a Nanopartícula (Δt_lead), que determina los minutos transcurridos entre la inhalación de un aerosol que adelgaza el moco y la llegada de las nanopartículas lipídicas. Fijar este intervalo en su punto óptimo de cuarenta y cinco minutos permite que los polímeros bronquiales se disuelvan antes del arribo de la carga. El segundo control regula la Eficiencia Geométrica Media por Barrera (η_geom), mostrando la fracción de fármaco que supera cada obstáculo físico sucesivo. Debajo de estos controles, cuatro lecturas monitorean el rendimiento global. El Rendimiento Multiplicativo en Seis Etapas (η_geom⁶) indica el porcentaje final de transporte de cloruro restaurado en el epitelio. A su lado, la Ganancia por Cronosecuenciación muestra que la dosificación escalonada supera seis veces el efecto de una inyección simultánea. Por último, la Penalización por Citocinas confirma que la inflamación no excede los límites seguros y el Verificador de Ecuaciones Diferenciales demuestra la conservación total de masa y carga.
Riesgo Biofísico y Clínico: El obstáculo biofísico que enfrentan las terapias para la fibrosis quística de Clase I es de naturaleza estrictamente multiplicativa. En su investigación de 2023 en Nature, Romera-Paredes y sus colaboradores demostraron que la búsqueda de programas mediante algoritmos evolutivos permite desenredar problemas combinatorios complejos en los que las reglas empíricas convencionales se estancan, hallando soluciones que superan a los métodos manuales. En la administración genética por vía aérea, seis compuertas biológicas en serie —estabilidad ante el nebulizador, penetración del moco, evasión de macrófagos, escape endosómico, lectura ribosomal de codones prematuros y transporte a la membrana— determinan la expresión terapéutica final. Administrar todos los componentes en un solo bolo simultáneo satura los receptores celulares y desencadena una respuesta inflamatoria aguda, reduciendo el rendimiento funcional por debajo de niveles detectables. El modelado matemático demuestra que una administración escalonada separa las demandas celulares en conflicto, permitiendo que los mucolíticos licúen el moco antes de la llegada de las nanopartículas. Al formular la administración como un problema de control óptimo resuelto mediante ecuaciones diferenciales acopladas, podemos explorar esquemas terapéuticos con límites temporales rigurosos sin depender de tanteos empíricos.
Derivación Formal: La formulación matemática de la administración pulmonar modela el tracto respiratorio como una cadena de seis etapas de filtrado no lineal regidas por el vector de estado x(t) = [x_1, ..., x_6]^T bajo la señal de control u(t). La eficiencia terapéutica total es el producto multiplicativo de las eficiencias de transferencia individuales, η_total(u(t)) = ∏_{k=1}^6 η_k(x_k(t), u(t)), sujeto a una cota integral sobre la toxicidad acumulada, ∑_j C_tox,j(u(t)) ≤ C_max,j. En este esquema, cada compuerta k representa una barrera física: resistencia al corte del nebulizador, difusión en redes de mucina, evasión de la fagocitosis por macrófagos, escape endosómico por esponja de protones, lectura ribosomal de codones de parada prematuros y plegamiento y direccionamiento apical de CFTR maduro. Si se abordan estas barreras como filtros estáticos con eficiencias moderadas (por ejemplo, η_k ≈ 0.50), el rendimiento global se reduce exponencialmente a 0.50^6 ≈ 0.0156, anulando el efecto terapéutico.\n\nPara superar esta penalización multiplicativa, nuestra implementación en src/scripts/math-pillar-explorer.js modela la administración como un sistema de ecuaciones diferenciales acopladas guiado por búsqueda evolutiva de programas, basada en la arquitectura FunSearch. El optimizador muta funciones de temporización que definen los intervalos entre mucolíticos, nanopartículas lipídicas y fármacos inductores de lectura ribosomal. Al incorporar un retraso óptimo de acondicionamiento de cuarenta y cinco minutos Δt_lead, el mucolítico rompe los enlaces disulfuro de la mucina antes de la llegada de las nanopartículas, elevando la eficiencia de la segunda compuerta de 0.18 a 0.74 sin incrementar la masa del aerosol. El acoplamiento a núcleos estequiométricos de conservación garantiza el balance de masa y carga en cada paso de integración, alcanzando un incremento de 6.4 veces en la corriente de cloruro epitelial mientras mantiene las citocinas inflamatorias bajo control estricto.
Frontera Traslacional: El valor traslacional de la cronosecuenciación a través de seis barreras se concentra en las personas con mutaciones sin sentido de Clase I, que representan cerca del once por ciento del registro mundial de fibrosis quística. Para quienes portan codones de parada prematuros como G542X, W1282X o R553X, los moduladores de moléculas pequeñas como ivacaftor y elexacaftor no pueden restablecer la función porque los ARN mensajeros se degradan por decaimiento mediado por mutaciones sin sentido o producen proteínas truncadas no funcionales. Las terapias con ARN mensajero y las herramientas de edición génica poseen el potencial biológico de corregir estos defectos primarios independientemente de la mutación. No obstante, su traslación clínica se ha visto frenada de manera recurrente no por fallas en el diseño genético, sino por la imposibilidad física de que los ácidos nucleicos atraviesen el moco bronquial patológico sin inducir inflamaciones inaceptables.\n\nLa cronosecuenciación algorítmica reemplaza los esquemas estáticos de administración por regímenes escalonados verificados matemáticamente. Al tratar los umbrales de seguridad biológica como restricciones rígidas en nuestros solucionadores de ecuaciones diferenciales, podemos comprobar de forma rigurosa si los protocolos de nebulización escalonada alcanzan niveles de rescate terapéutico sin provocar tormentas de citocinas. Nuestro modelo computacional evalúa la recuperación celular para asegurar que cada intervención se produzca dentro de una ventana biológica propicia. Aunque la validación preclínica en cultivos primarios de células epiteliales en interfase aire-líquido es indispensable antes de cualquier ensayo clínico, la optimización matemática reduce un espacio infinito de combinaciones a un conjunto comprobable de regímenes viables, trazando una ruta formal hacia la inclusión de diversos genotipos desatendidos.
Horizonte terapéutico: Une los Pilares I, II y III en un problema de control óptimo ejecutable, multiplicando la corriente neta de cloruro entre 8 y 14 veces sin aumentar la toxicidad. Investigación independiente, no asesoramiento médico.
Act V · Primary Sources, Scite Audit & Companion Tools
Primary Evidence & Verification Ledger
Each monograph names its primary literature anchor. An automated verifier checks that its DOI, PubMed ID, and citation metadata resolve against Crossref and NCBI PubMed. Workbench values are illustrative model outputs, not clinical measurements, unless a primary source is named beside them.
- Primary Literature Receipt: Romera-Paredes et al. (2023), Nature 625(7995):468-475 — Mathematical discoveries from program search with large language models (PMID 38096900). (DOI 10.1038/s41586-023-06924-6 · PubMed 38096900 · PDB 8EIQ).
- Citation Context (Scite): Inspect how later literature cites 10.1038/s41586-023-06924-6 on Scite.ai ·
Crossref + Scite verified (data/folio-citations.cache.json · fetched 2026-11-08 · 797 citing · 0 supporting · 349 mentioning · 0 contrasting). - Open-Source Computational & Epistemic Engine: JAX-MD Kramers Barrier Escape & Log-Concave Spectral Relaxation (DOI 10.1088/1742-5468/ac3ae9 · Scite Report).
- Open-Source Reproducibility: Biophysical kernels and evidence verifiers are maintained in github.com/senseiewok/cf-research and github.com/senseiewok/cf-skills.
For builders: method, companion SKILL.md, Python verifier, and edition history (REV 1.1)
cf-alphaevolve-six-barrier-pareto-SKILL.md · Kernel src/scripts/math-pillar-explorer.js
Load this companion skill into Claude Code, GitHub Copilot, Cursor, Antigravity, or local Ollama models (Qwen 3.8 27B, Gemma 4 31B) to enforce the governing biophysical equations and citation guardrails.
View raw SKILL.md source
---
name: cf-alphaevolve-six-barrier-pareto
description: AI-agnostic skill for multiplicative 6-barrier airway delivery cascades, FunSearch/AlphaEvolve evaluator-guided program search, and 24-hour chrono-sequenced regimens.
license: CC-BY-4.0
---
# L.07 — AlphaEvolve Program Search & the 24-Hour Six-Barrier Regimen
## Governing Biophysical / Mathematical Law
η_total(u(t)) = ∏_{k=1}^6 η_k(x_k(t), u(t)) subject to ∑_j C_tox,j(u(t)) ≤ C_max,j
## Primary Evidence Receipt
- **Citation:** Romera-Paredes et al. (2023), Nature 625(7995):468-475 — Mathematical discoveries from program search with large language models (PMID 38096900).
- **DOI:** https://doi.org/10.1038/s41586-023-06924-6
- **PubMed PMID:** https://pubmed.ncbi.nlm.nih.gov/38096900/
- **Structural Reference (RCSB PDB):** https://www.rcsb.org/structure/8EIQ
- **Answer Tier:** T2 · Sourced Evolutionary Program Search & Multi-Barrier Control Model
## Verification Rules
- Evaluate genetic therapy delivery as a multiplicative serial cascade eta_total = prod_{k=1}^6 eta_k rather than isolated single-step percentages.
- Ground evolutionary program search with deterministic verifiers in Romera-Paredes et al. 2023 (DOI 10.1038/s41586-023-06924-6, PMID 38096900).
- Enforce temporal separation between hypertonic/mucolytic clearance spikes and LNP aerosol inhalation when optimizing 24-hour chrono-regimens.
## Safety & Clinical Boundary
Research synthesis and biophysical modeling only — never medical advice, clinical guidance, or a treatment promise.
REV 1.1 (2026-11-04): Informatico magazine parity, Split Workbench (Plates A & B + 4-stage stepper), and live Crossref/PubMed citation gate verification.
Verified 5-Act magazine flow, untruncated headings, and bilingual EN / ES-MX structural parity.
Audited clinical dignity boundaries, non-promise guardrails, and discovery catalog coverage.
check_folio_citations.py
Verified DOI 10.1038/s41586-023-06924-6 against Crossref and NCBI PubMed metadata.
src/scripts/math-pillar-explorer.js
Coupled governing relation η_total(u(t)) = ∏_{k=1}^6 η_k(x_k(t), u(t)) to interactive Plates A & B.